A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis - Wikidata - wikimedia - TriplyDB

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q28240241

about

Ambulatory and short-burst oxygen for interstitial lung disease Asbestosis and environmental causes of usual interstitial pneumonia Ambulatory and short-burst oxygen for interstitial lung disease Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD Exercise training in idiopathic pulmonary fibrosis: is it of benefit?Therapeutic Approach to Adult Fibrotic Lung Diseases Recent advances in understanding idiopathic pulmonary fibrosis Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis Cardiac manifestations of idiopathic pulmonary fibrosis Pharmacological management of IPF Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis New perspectives on management of idiopathic pulmonary fibrosis Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib Role and New Insights of Pirfenidone in Fibrotic Diseases Lung transplantation in IIP: A review Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis Managing comorbidities in idiopathic pulmonary fibrosis Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers IPF clinical trial design and endpoints Interstitial lung disease: raising the index of suspicion in primary care Open-access biorepository for idiopathic pulmonary fibrosis. The way forward Smoking-related interstitial lung disease Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis Molecular mechanism and treatment of viral hepatitis-related liver fibrosis.Idiopathic Pulmonary Fibrosis: Treatment and Prognosis Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis The extracellular matrix - the under-recognized element in lung disease?Update on diagnosis and treatment of idiopathic pulmonary fibrosis Update on therapeutic management of idiopathic pulmonary fibrosis Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease

P2860

Q24187647-8C8AAC47-7F41-4EEE-A2F5-FBE996E9CFBE Q26159097-CB19B1AD-9545-40A7-86EB-74182B525F49 Q26471157-5A6FD98D-B1C2-4556-8C14-26E65E187641 Q26738458-35121254-31B3-4D8B-B391-2DBED79BC1FF Q26740540-699D7ABB-D0A2-459D-A48A-87113638E402 Q26740857-07A013E6-4817-4772-B683-C41AC18B06FD Q26741569-B74D320A-462A-430B-BD22-938DB077D009 Q26745905-787B934B-5EAC-49E0-BA5E-5B3F692C5EEE Q26747694-26BAE7CC-5A80-4110-8531-49C7CF3B2AB7 Q26748176-6B6F030E-F6FA-4AAC-88B7-B1AE99987D87 Q26748808-255D4FFD-F36A-410C-8A5E-C84D3ED6B761 Q26750418-D7D638E0-0891-4471-8A3F-F0A8D3F719E7 Q26765586-B26B614A-DCD0-4ADE-8FB7-F5350E9A3D64 Q26766313-64AA1B43-06A9-4B6A-A0F8-C6D1DA573420 Q26770376-CEE3D22F-DA18-4550-9F98-103FCC982679 Q26771309-1378259A-5D3B-4D86-92C0-958DA147F8F9 Q26771647-12B376DC-4630-4B2D-A45A-F08272C7443D Q26774154-5268DAAB-1EE9-4AFF-8380-DC922B1C794E Q26774870-52115DEF-ADB3-41B6-AFCE-5F6F2BD80559 Q26775753-6F2587B2-3304-41A2-A5A0-E6DD80236FE3 Q26777928-E9C0467B-53D3-453C-B188-3F394BD300B3 Q26781255-6E0FA06B-2254-4ED8-9BBB-2AF5F7F50E6C Q26783169-C1841F95-64EC-4FE6-A25B-250160E22011 Q26785617-26826305-8475-4196-8402-8CA69E532525 Q26797272-9041A5D9-56A0-44FC-8B36-ACB9756D90B8 Q26801150-9B9BCB7A-9E33-45CA-857D-527899FF08D0 Q26864836-81D3F830-1A7A-4F85-873E-074E04E818B0 Q26995648-A7A7E78E-9FD7-4865-A770-EE5D7D90C230 Q27001028-F2E4F55C-844B-48B6-8523-8C87AEA7CE98 Q27003322-04175A1E-82CD-4689-9ED5-5BFB4B8689BC Q27027779-A59B6171-CA72-4A30-B787-ED9995AC6543 Q27309770-422B4783-6E1F-49C1-986A-F7922930F924 Q27333960-3BFF9CF6-B651-4A6F-B4BA-F5279CE3CD82 Q27692609-39407A45-F439-4AB6-9C1D-2C734DB6B7EB Q28073641-6F459D4E-08EB-4CA8-BFA1-51E14A15D002 Q28075536-B80A760D-CE15-42E6-91DD-0AC58F3EB52C Q28075842-F0B0AEE1-61A2-4C94-9B21-A473963B1622 Q28083702-5CBDAE98-8AEA-4E80-8AD1-9B3D05736279 Q28083944-F3F2D5B1-A00C-4EF5-88F2-D81A80AD8B6D Q28085094-2EF0F7ED-EBD4-4EFB-9000-074AFB0FEB15

P2860

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q28240241

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年5月29日に発表された論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@ast

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@en

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@nl

特発性肺線維症患者におけるピルフェニドンの第3相試験

@ja

type

label

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@ast

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@en

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@nl

特発性肺線維症患者におけるピルフェニドンの第3相試験

@ja

prefLabel

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@ast

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@en

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@nl

特発性肺線維症患者におけるピルフェニドンの第3相試験

@ja

P1433

Q28240241-6A153B56-0828-4DB6-82F8-B91401DBFC7D

P1476

Q28240241-9C425262-EC3F-44BE-AEF1-05E7F1FF8675

P2093

Q28240241-019B3C79-6B33-4305-BC9D-BE2B87672905

Q28240241-233A0705-FBAF-4FB7-8B1D-3575669B8E2D

Q28240241-3A392CBA-1C54-4F60-B097-47B0F931F38F

Q28240241-3C7A6257-F55B-4688-AB85-F2EF085D397F

Q28240241-4151226A-156C-4EE7-B5BF-499961953516

Q28240241-449E7B58-2B68-4907-95FB-8B04B737BDA0

Q28240241-45CB4173-56F6-467A-A8DC-CCF16A78698D

Q28240241-464E9CA1-090A-4B73-923E-1025B10DBCA6

Q28240241-4C32A60B-1F9F-44F6-8DCE-8A5984DE22BA

Q28240241-50F48BCB-A5E8-4BB1-A8F0-E6BA6FDF1FD7

P304

Q28240241-9E58972E-A947-49EB-8813-E491AF3CD376

P31

Q28240241-DBA03755-D9C5-4ADF-818E-D4BEB63B8ADA

P3181

Q28240241-A975237C-C439-4EDC-9CA6-3AAFBAC74892

P356

Q28240241-ECC43038-75AD-4841-A374-B691B85AFE31

P407

Q28240241-BA75BE6D-E23B-4E1D-A512-6442EA92BD88

P433

Q28240241-D90F4A1C-B815-48A4-BCCC-00F35C0BAD7D

P478

Q28240241-D7996A58-EA9E-469D-9F71-73ED61DF7542

P577

Q28240241-F58421BD-D025-4B34-A527-2236C1B0720B

P698

Q28240241-09D804F2-8DC7-4581-A511-8936646F1FD5

P921

Q28240241-66F2593A-2373-4234-A2C7-EE33C33B1734

Q28240241-7CC00E0C-6CD7-4251-857D-E7EC38730566

Q28240241-A6079E11-D635-45D7-92E8-3DDC25CA5C6A

P3181

P356

P1433

The New England Journal of Medicine

P1476

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

@en

P2093

Carlos A Pereira

http://www.w3.org/2001/XMLSchema#string

David J Lederer

http://www.w3.org/2001/XMLSchema#string

David Kardatzke

http://www.w3.org/2001/XMLSchema#string

Eduard Gorina

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Fagan

http://www.w3.org/2001/XMLSchema#string

Ian Glaspole

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Swigris

http://www.w3.org/2001/XMLSchema#string

Lisa Lancaster

http://www.w3.org/2001/XMLSchema#string

Marilyn K Glassberg

http://www.w3.org/2001/XMLSchema#string

Paul W Noble

http://www.w3.org/2001/XMLSchema#string

P304

2083-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

10745

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1402582

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24836312

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

phase III clinical trial